Posted by Michael Wonder on 05 Sep 2023
NICE recommends Chiesi’s Elfabrio for adults with Fabry disease
4 September 2023 - NICE has recommended Chiesi’s Elfabrio (pegunigalsidase alfa) as a long-term option for treating Fabry disease in adults in England and Wales.
The NICE committee concluded that the treatment would be an additional enzyme replacement therapy for patients with and without an amenable mutation and was a relevant comparator to existing treatments.
